Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01479621 · ClinicalTrials.gov registry record · Phase 2
A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids
A Phase 2 study, sponsored by Teva Branded Pharmaceutical Products R&D.
- Completed
- Registry status
- Phase 2
- Development phase
- 909
- Enrollment target
NCT01479621 is a Phase 2 study that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 909 participants.
The verdict
NCT01479621, a Phase 2 study, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 909 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo- and open-label active controlled, parallel-group, multicenter, dose ranging study in male or female subjects ages 12 years and older with persistent asthma who are uncontrolled on non-steroidal therapy. The primary objective of this study is to evaluate the dose response, efficacy and safety of 4 different doses of fluticasone propionate delivered as Fluticasone Propionate DPI (Dry Powder Inhaler) when administered twice daily.
Interventions
- DRUG Placebo MDPI
- DRUG Fp MDPI
- DRUG albuterol/salbutamol
- DRUG Flovent Diskus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 909 participants |
| Start Date | 2012-01 |
| Est. Completion | 2013-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01479621
The ClinicalTrials.gov registry entry for NCT01479621 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 909 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Branded Pharmaceutical Products R&D, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo MDPI is the first listed.
NCT01479621 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01479621 about?
NCT01479621 is a clinical study titled "A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids". This is a randomized, double-blind, placebo- and open-label active controlled, parallel-group, multicenter, dose ranging study in male or female subjects ages 12 years and older with persistent asthma who are uncontrolled on non-steroidal therapy. The primary objective of this study is to evaluate t...
What is the current status of trial NCT01479621?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 909 participants. The study started on 2012-01. Estimated completion is 2013-07.
What interventions are being tested in trial NCT01479621?
The interventions under investigation include: Placebo MDPI (DRUG), Fp MDPI (DRUG), albuterol/salbutamol (DRUG), Flovent Diskus (DRUG).
Who is sponsoring clinical trial NCT01479621?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.